{"title": "Nanopore target sequencing for accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses", "doi": "10.1101/2020.03.04.20029538", "citation_id": "2020.03.04.20029538v1", "date": "2020-03-06", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.04.20029538", "abstract": "<p>The ongoing novel coronavirus pneumonia COVID-19 outbreak in Wuhan, China, has engendered numerous cases of infection and death. COVID-19 diagnosis relies upon nucleic acid detection; however, current recommended methods exhibit high false-negative rates, low sensitivity, and cannot identify other respiratory virus infections, thereby resulting patient misdiagnosis and impeding epidemic containment. Combining the advantages of target amplification and long-read, real-time nanopore sequencing, we developed nanopore target sequencing (NTS) to detect SARS-CoV-2 and other respiratory viruses simultaneously within 6-10 h. Parallel testing with approved qPCR kits of SARS-CoV-2 and NTS using 61 nucleic acid samples from suspected COVID-19 cases confirmed that NTS identified more infected patients as positive, and could also monitor for mutated nucleic acid sequence or other respiratory virus infection in the test sample. NTS is thus suitable for contemporary COVID-19 diagnosis; moreover, this platform can be further extended for diagnosing other viruses or pathogens.</p>", "twitter_description": "The ongoing novel coronavirus pneumonia COVID-19 outbreak in Wuhan, China, has engendered numerous cases of infection and death. COVID-19 diagnosis relies upon nucleic acid detection; however, current recommended methods exhibit high false-negative rates, low sensitivity, and cannot identify other respiratory virus infections, thereby resulting patient misdiagnosis and impeding epidemic containment. Combining the advantages of target amplification and long-read, real-time nanopore sequencing, we developed nanopore target sequencing (NTS) to detect SARS-CoV-2 and other respiratory viruses simultaneously within 6-10 h. Parallel testing with approved qPCR kits of SARS-CoV-2 and NTS using 61 nucleic acid samples from suspected COVID-19 cases confirmed that NTS identified more infected patients as positive, and could also monitor for mutated nucleic acid sequence or other respiratory virus infection in the test sample. NTS is thus suitable for contemporary COVID-19 diagnosis; moreover, this platform can be further extended for diagnosing other viruses or pathogens.\n\n### Competing Interest Statement\n\nWuhan Dgensee Clinical Laboratory Co., Ltd have applied patents on this new strategy.\n\n### Funding Statement\n\nThis project was supported by Wuhan Dgensee Clinical Laboratory Co., Ltd.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data generated or used during the study appear in the submitted article.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20029538v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20029538v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20029538v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/06/2020.03.04.20029538.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.04.20029538v1", "access_rights": "restricted", "authors": ["Ming Wang", "Aisi Fu", "Ben Hu", "Yongqing Tong", "Ran Liu", "Jiashuang Gu", "Jianghao Liu", "Wen Jiang", "Gaigai Shen", "Wanxu Zhao", "Dong Men", "Lilei Yu", "Zixin Deng", "Yan Li", "Tiangang Liu"]}